Immunotherapy for lung cancer with pulmonary fibrosis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09215
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Nakamura Yutaro 浜松医科大学, 医学部附属病院, 講師 (60436962)
• Co-Investigator(Kenkyū-buntansha): 須田 隆文 浜松医科大学, 医学部, 教授 (30291397)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 免疫療法 / 樹状細胞 / 肺癌

Outline of Final Research Achievements

Lung cancer is the most deadly cancer in Japan. Type-1 immune response play a critical role in anti-tumor response via dendritic cells (DCs). We previously developed type-1 polarized DCs (DC1s), which induced strong anti-tumor effect in various animal tumor models. Here we showed that human DC1s significantly produced chemokines associated with type-1 immune resposnse. Furthermore human DC1s activated NK cells, and suppressed the proliferation of regulatory T cells. DC1s is a promising candidate for combination cancer therapy with currently available drugs.

Free Research Field

呼吸器内科学